Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
Allakos Inc. reports developments as a biotechnology company that has developed antibody therapeutics for allergic, inflammatory and proliferative diseases. Company news has centered on AK006, a Siglec-6 monoclonal antibody designed to inhibit mast cells, including Phase 1 safety, pharmacokinetic, pharmacodynamic and chronic spontaneous urticaria results.
Recent updates also cover the discontinuation of AK006 development, restructuring activities to reduce costs, exploration of strategic alternatives, financial results and cash-position commentary. Other recurring items include material agreements, capital-structure disclosures and governance matters tied to the company’s public-company status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Allakos Inc. (Nasdaq: ALLK) provided a business update on March 6, 2023, reporting financial results for Q4 and full year 2022. Key developments include the initiation of a Phase 2b study of lirentelimab for chronic spontaneous urticaria and continued enrollment for atopic dermatitis. The company reported Q4 2022 research and development expenses of $35.4 million, down from $72.9 million in Q4 2021, attributed to cost-cutting measures. General and administrative expenses also decreased to $10.8 million from $23.2 million. The net loss shrank to $43.0 million from $94.4 million year-over-year, and cash reserves stood at $279.8 million.